Related Experiment Videos
Embryo associated immunosuppressor factor (EASF) and serum estradiol synergism in pre-embryonic development after in
1Department of Obstetrics Gynaecology and Reproductive Sciences, University of Manitoba, Winnipeg, Canada.
The aim of this study was to test whether the level of serum immunosuppressor factor (EASF) and serum estradiol (E2) play a cooperative role in the pre-implantation early embryonic development in IVF-patients. Serum samples were collected from 80 patients undergoing IVF-ET and the level of EASF in patient's sera was assayed using a two-site sandwich enzyme linked immunosorbent assay (ELISA) system. Two-hundred fifty-one IVF-culture media were obtained from these patients and the EASF activity was measured using concanavalin A-induced lymphocyte proliferation assay. EASF activity in embryo growth media, quality of ova, number of cells in each pre-embryo at the time of embryo transfer, cycle day 3 serum E2 and peak E2 levels were correlated with pregnancy outcome. Thirty-three out of 80 patients had detectable levels of serum EASF. The number of pre-embryos with > 4 cell stage at the time of embryo transfer correlated with the total number of ova retrieved in patients positive for serum EASF (P = 0.01) and patients that had an ongoing pregnancy at 7-8 weeks (P < 0.01). Ratio of the number of pre-embryos with > 4 cell stage at the time of embryo transfer and total number of ova retrieved correlated with cycle day 3 serum E2 (P < 0.01) and peak E2 (P = 0.01) levels only in patients positive for EASF. The EASF activity of embryo growth media correlated with cycle day 3 serum E2 (P = 0.0001) and peak E2 (P = 0.007) levels only in patients that were positive for EASF and got pregnant after IVF-ET. This study suggests that the levels of serum EASF and E2 may act synergistically in the development of early embryo.
The aim of this study was to test whether the level of serum immunosuppressor factor (EASF) and serum estradiol (E2) play a cooperative role in the pre-implantation early embryonic development in IVF-patients. Serum samples were collected from 80 patients undergoing IVF-ET and the level of EASF in patient's sera was assayed using a two-site sandwich enzyme linked immunosorbent assay (ELISA) system. Two-hundred fifty-one IVF-culture media were obtained from these patients and the EASF activity was measured using concanavalin A-induced lymphocyte proliferation assay. EASF activity in embryo growth media, quality of ova, number of cells in each pre-embryo at the time of embryo transfer, cycle day 3 serum E2 and peak E2 levels were correlated with pregnancy outcome. Thirty-three out of 80 patients had detectable levels of serum EASF. The number of pre-embryos with > 4 cell stage at the time of embryo transfer correlated with the total number of ova retrieved in patients positive for serum EASF (P = 0.01) and patients that had an ongoing pregnancy at 7-8 weeks (P < 0.01). Ratio of the number of pre-embryos with > 4 cell stage at the time of embryo transfer and total number of ova retrieved correlated with cycle day 3 serum E2 (P < 0.01) and peak E2 (P = 0.01) levels only in patients positive for EASF. The EASF activity of embryo growth media correlated with cycle day 3 serum E2 (P = 0.0001) and peak E2 (P = 0.007) levels only in patients that were positive for EASF and got pregnant after IVF-ET. This study suggests that the levels of serum EASF and E2 may act synergistically in the development of early embryo.